Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
CSPC PHARMA's New Drug JMT108 Obtains Clinical Trial Approval in CN
Recommend 15 Positive 14 Negative 12 |
||||
|
||||
|
CSPC PHARMA (01093.HK) announced that JMT108, a new Class I bi-functional fusion protein drug developed by the group, has been approved by the National Medical Products Administration to conduct clinical trials in China. This product is a recombinant fully human anti-PD-1/IL-15 bi-functional fusion protein. The indication for this approval is advanced malignant tumors. According to CSPC PHARMA, preclinical studies demonstrated that this product had a broad variety of indications with significant anti-tumor effects and a good safety profile in multiple malignant tumor models, providing a promising clinical development value. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
